全文获取类型
收费全文 | 6412篇 |
免费 | 528篇 |
国内免费 | 145篇 |
专业分类
耳鼻咽喉 | 72篇 |
儿科学 | 166篇 |
妇产科学 | 44篇 |
基础医学 | 507篇 |
口腔科学 | 144篇 |
临床医学 | 507篇 |
内科学 | 349篇 |
皮肤病学 | 151篇 |
神经病学 | 133篇 |
特种医学 | 629篇 |
外国民族医学 | 6篇 |
外科学 | 605篇 |
综合类 | 868篇 |
预防医学 | 519篇 |
眼科学 | 71篇 |
药学 | 512篇 |
4篇 | |
中国医学 | 233篇 |
肿瘤学 | 1565篇 |
出版年
2024年 | 3篇 |
2023年 | 54篇 |
2022年 | 93篇 |
2021年 | 148篇 |
2020年 | 157篇 |
2019年 | 110篇 |
2018年 | 160篇 |
2017年 | 175篇 |
2016年 | 157篇 |
2015年 | 169篇 |
2014年 | 312篇 |
2013年 | 479篇 |
2012年 | 355篇 |
2011年 | 386篇 |
2010年 | 321篇 |
2009年 | 273篇 |
2008年 | 326篇 |
2007年 | 314篇 |
2006年 | 270篇 |
2005年 | 275篇 |
2004年 | 217篇 |
2003年 | 201篇 |
2002年 | 213篇 |
2001年 | 156篇 |
2000年 | 157篇 |
1999年 | 131篇 |
1998年 | 105篇 |
1997年 | 105篇 |
1996年 | 105篇 |
1995年 | 116篇 |
1994年 | 89篇 |
1993年 | 60篇 |
1992年 | 73篇 |
1991年 | 68篇 |
1990年 | 60篇 |
1989年 | 58篇 |
1988年 | 60篇 |
1987年 | 63篇 |
1986年 | 46篇 |
1985年 | 85篇 |
1984年 | 62篇 |
1983年 | 65篇 |
1982年 | 66篇 |
1981年 | 54篇 |
1980年 | 54篇 |
1979年 | 40篇 |
1978年 | 17篇 |
1977年 | 5篇 |
1976年 | 6篇 |
1975年 | 6篇 |
排序方式: 共有7085条查询结果,搜索用时 15 毫秒
1.
《Cancer radiothérapie》2022,26(4):542-546
PurposeModerate hypofractionated radiotherapy has become routine practice for a selected population of patients treated for early-stage breast cancer. In April 2020, the Fast Forward (FF) study was published which introduced another extreme hypofractionated radiotherapy regimen in five sessions over a week. The aim of this work is to evaluate the population of first patients in whom this regimen was used in our department, as well as the results in terms of early toxicity.Material and methodsWe retrospectively analysed all the patients treated in our department according to the Fast Forward protocol after establishing an institutional consensus regarding the selection of patients with breast cancer without indication for lymph node irradiation. All patients received breast-only irradiation at a total dose of 26 Gy in five fractions according to protocol. All patients were treated by modern conformational techniques with planning large volume coverage between 95 and 100%. Acute toxicity of the treatment was assessed using the NCI CTC v4.0 scale and the general condition was assessed according to the WHO classification.ResultsBetween August 2020 and May 2021, 30 patients were included, treated on the breast alone without complement on the tumour bed or irradiation of the lymph node areas. The median age of the patients was 80 years (range: 60–85 years) with performance status 2 in 27 cases (89%). Only one patient had metastatic disease (3%), one patient presented locally advanced and 28 (94%) patients had early stage disease. Three patients (10%) were treated in dorsal decubitus according to the “field in the field” technique and 27 patients (90%) in isocentric lateral decubitus, which made it possible to avoid the organs at risk such as the heart (average dose of less than 1 Gy) and the lungs. The early toxicity observed was grade I radio dermatitis in 8 patients (27%). No grade 2 and 3 toxicity, as well as radiation-induced pain or lymphedema were observed.ConclusionsThe results of this series of patients treated with hypofractionated radiotherapy according to the Fast Forward protocol on the breast alone with adapted techniques show that the protocol is feasible, with little early toxicity but a greater follow-up is necessary to assess long-term toxicity. 相似文献
2.
3.
4.
5.
Tomoya Kurokawa Takuya Nakagawa Keisuke Matsusaka Masaki Fukuyo Masato Mima Kiyoshi Misawa Bahityar Rahmutulla Jun‐ichiro Ikeda Toyoyuki Hanazawa Yoshitaka Okamoto Atsushi Kaneda 《Cancer science》2020,111(4):1407-1416
Irradiation, or chemoradiotherapy, is a curative treatment for oropharyngeal squamous cell carcinoma (OPSCC). Its invasiveness, however, can often negate its efficacy. Therefore, developing methods to predict which patients would benefit from irradiation is urgent. Promoter DNA hypermethylation was recently reported to correlate with favorable OPSCC prognosis. It is still unclear, however, whether there is an association between promoter DNA methylation and response to irradiation. In this study, we analyzed DNA methylation in the specimens from 40 OPSCC patients who had undergone irradiation, using the Infinium assay. Our results showed significant correlation between high levels of promoter DNA methylation and better response to treatment (P < 0.01). We used the 10 most differentially‐methylated genes between responders and non–responders to develop a panel of predictive markers for efficacy. Our panel had high sensitivity, specificity and accuracy (92%, 93% and 93%, respectively). We conducted pyrosequencing to quantitatively validate the methylation levels of 8 of the 10 marker genes (ROBO1, ULK4P3, MYOD1, LBX1, CACNA1A, IRX4, DPYSL3 and ELAVL2) obtained by Infinium. The validation by pyrosequencing showed that these 8 genes had a high prediction performance for the training set of 40 specimens and for a validation set of 35 OPSCC specimens, showing 96% sensitivity, 89% specificity and 94% accuracy. Methylation of these markers correlated significantly with better progression‐free and overall survival rates, regardless of human papillomavirus status. These results indicate that increased DNA methylation is associated with better responses to irradiation therapy and that DNA methylation can help establish efficacy prediction markers in OPSCC. 相似文献
6.
《中国现代医生》2020,58(19):119-122+封三
目的 探讨实时超声引导微波消融术治疗子宫腺肌瘤的临床应用。方法 选取2015年1月~2019年1月收入我院子宫腺肌瘤患者37例为研究对象。采用超声造影评价患者的腺肌瘤消融率,常规超声评价瘤体缩小率。采用临床疗效评定标准来评价患者临床症状改善情况。结果 痛经改善率为78.9%(15/19),月经失调改善率为42.9%(9/21),贫血改善率为55.6%(10/18)。超声造影显示仅3例出现消融不完全,消融有效率为91.9%,术后行补充消融治疗,37例局限性子宫腺肌瘤平均消融率均达90%以上。与治疗前比较,治疗后3、6、12个月患者瘤体缩小率分别为60.8%、78.1%、93.1%,差异有统计学意义(P0.05)。与治疗前比较,治疗后临床症状有改善。结论实时超声引导微波消融术治疗子宫腺肌瘤患者,能够减小腺肌瘤体积,且能够明显改善患者临床症状,为子宫肌瘤患者提供新的治疗手段。 相似文献
7.
8.
《Cancer radiothérapie》2022,26(4):611-615
In order to provide more convenient irradiation regimens for patient comfort, radiation facility organization and health expenses, new hypofractionated protocols have been evaluated. Moderately (dose/fraction: 2.3 to 3 Gy), then ultra (dose/fraction: 5.2 to 6.1 Gy) hypofractionated irradiations were first validated. The current question is: is it possible to go forward using extreme hypofractionated regimens (EHR) based on 1 to 3 fractions. Different irradiation techniques are under investigation. However, brachytherapy remains the smartest way to deliver a high dose in a small volume. We report prospective and retrospective study results which evaluated EHR for breast and prostate brachytherapy. While oncological outcome and toxicity profile appear extremely encouraging for low-risk breast cancer after a 1 to 4 fractions (6.25 to 20 Gy/fraction), the use of a single fraction of 19 to 23 Gy appears debatable for prostate cancer. Brachytherapy represents an emblematic example of EHR but longer follow-up and more mature results are awaited in order to specify the right indications and refine the EQD2 calculation method including new biological and technical factors. 相似文献
9.
Nicolas Zhou Matthew Bott Bernard J. Park Eric Vallières Candice L. Wilshire Kazuhiro Yasufuku Jonathan D. Spicer David R. Jones Boris Sepesi 《The Journal of thoracic and cardiovascular surgery》2021,161(3):760-771.e2
BackgroundAdjuvant chemotherapy, postoperative radiation (PORT), and prophylactic cranial irradiation (PCI) have been individually examined in limited-stage small cell lung cancer (SCLC). There is a paucity of data on the effectiveness of each adjuvant treatment modality when used in combination after surgical resection of SCLC.MethodsData were collected from 5 cancer centers on all patients with limited-stage SCLC who underwent surgical resection between 1986 and 2019. Univariate and multivariable models were conducted to identify predictors of long-term outcomes, focusing on freedom from recurrence and survival benefit of adjuvant chemotherapy, PORT, and PCI.ResultsA total of 164 patients were analyzed. Multivariable Cox regression analysis did not identify any adjuvant therapies to significantly influence recurrence in this cohort. Specifically, PORT was not associated with a significant influence on locoregional recurrence and PCI was not significantly associated with intracranial outcomes. Adjuvant chemotherapy improved survival in all stage I through III disease (hazard ratio, 0.49; 95% confidence interval, 0.29-0.81; P = .005) and even in pathologically node negative patients (hazard ratio, 0.49; 95% confidence interval, 0.27-0.91; P = .024). Although PCI was found to improve survival in univariate analysis, it was not significant in a multivariable model. PORT was not found to affect survival on either univariate or multivariable analysis.ConclusionsThis is among the largest multi-institutional studies on surgically resected limited-stage SCLC. Our results highlight survival benefit of adjuvant chemotherapy, but did not identify a statistically significant influence from mediastinal PORT or PCI in our cohort. Larger prospective studies are needed to determine the benefit of PORT or PCI in a surgically resected limited-stage SCLC population. 相似文献
10.
Roberto L. Cazzato Pierre De Marini Ian Leonard-Lorant Danoob Dalili Guillaume Koch Pierre A. Autrusseau Theo Mayer Julia Weiss Pierre Auloge Julien Garnon Afshin Gangi 《Diagnostic and interventional imaging》2021,102(6):355-361
PurposeTo retrospectively report on safety, pain relief and local tumor control achieved with percutaneous ablation of sacral bone metastases.Materials and methodsFrom February 2009 to June 2020, 23 consecutive patients (12 women and 11 men; mean age, 60 ± 8 [SD] years; median, 60; range: 48-80 years) with 23 sacral metastases underwent radiofrequency (RFA) or cryo-ablation (CA), with palliative or curative intent at our institution. Patients’ demographics and data pertaining to treated metastases, procedure-related variables, safety, and clinical evolution following ablation were collected and analyzed. Pain was assessed with numerical pain rating scale (NPRS).ResultsSixteen (70%) patients were treated with palliative and 7 (30%) with curative intent. Mean tumor diameter was 38 ± 19 (SD) mm (median, 36; range: 11-76). External radiation therapy had been performed on five metastases (5/23; 22%) prior to ablation. RFA was used in 9 (39%) metastases and CA in the remaining 14 (61%). Thermo-protective measures and adjuvant bone consolidation were used whilst treating 20 (87%) and 8 (35%) metastases, respectively. Five (22%) minor complications were recorded. At mean 31 ± 21 (SD) (median, 32; range: 2-70) months follow-up mean NPRS was 2 ± 2 (SD) (median, 1; range: 0–6) vs. 5 ± 1 (median, 5; range: 4–8; P < 0.001) at the baseline. Three metastases out of 7 (43%) undergoing curative ablation showed local progression at mean 4 ± 4 (SD) (median, 2; range: 1-8) months follow-up.ConclusionPercutaneous ablation of sacral metastases is safe and results in significant long-lasting pain relief. Local tumor control seems sub-optimal; however, further investigations are needed to confirm these findings due to paucity of data. 相似文献